Labiotech.eu

Pfizer’s strategy: how the company is evolving after its COVID success

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

Is Pfizer Stock an Underrated Healthcare Investment Play?

Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.

Pfizer wins full FDA approval for Braftovi in colorectal cancer

Pfizer (PFE) stock is in focus as the FDA grants full approval for its colorectal cancer drug Braftovi, developed with Ono Pharmaceutical (OPHLF). Read more here.

Pfizer Ponders Viagra Lessons to Chart First Obesity Drug Launch

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine.
Business Wire

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination ...
Precision Medicine Online

Pfizer Braftovi-Based Triplet for BRAF-Mutant Metastatic CRC Converts to Full FDA Approval

Phase III data show the Braftovi regimen significantly improves overall survival and response versus chemo as a frontline treatment for advanced tumors.